Navigation Links
Phase 2 Data for Ultra-Long-Acting Insulin Degludec Shows the Potential to Effectively Lower Blood Sugar, Including When Used Three Times a Week
Date:6/25/2010

ORLANDO, Fla., June 25 /PRNewswire-FirstCall/ -- Novo Nordisk today presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycemic control when used once daily or three times weekly. These data were presented at the 70th Scientific Sessions of the American Diabetes Association (ADA).(1)

These phase 2 studies showed that insulin degludec helped improve glucose control. In one study, after 16 weeks of treatment with insulin degludec, mean HbA1c reductions were similar across the once-daily and three-times-weekly insulin degludec groups (-1.3% and -1.5% respectively) and comparable to insulin glargine (-1.5%).(2)

In this study, 77% of patients treated with insulin degludec three times weekly did not experience any confirmed hypoglycemia (defined as low blood glucose levels or episodes that required assistance). This result was similar in the study arm using insulin glargine once daily. Of those patients using insulin degludec once daily, 92% did not experience any confirmed hypoglycemia. A formal statistical test was not possible due to low number of patients in this study (60-62 in each arm).

"Insulin degludec has shown the potential to help deliver improvements in glycemic control with less than one daily injection," said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. "The low rate of hypoglycemia after once-daily insulin degludec administration, as well as the potential to be used three times weekly in people with type 2 diabetes will be further evaluated in our pivotal phase 3 trials in the BEGIN™ and BOOST™ programs."

Insulin degludec/insulin aspart (IDegAsp), a combination-insulin with insulin degludec and insulin aspart, is being tested in the BOOST™ program. It is being studied for its ability to provide the ultra-long-acting basal coverage of insulin degludec as well as a bolus boost to cover the meal coinciding with the injection. Phase 2 data presented at ADA showed that IDegAsp once daily brought the majority of patients to ADA-recommended glycemic targets (<7% HbA1c) without confirmed major hypoglycemia after 16 weeks of treatment.(3) In this proof-of-concept trial, there were 60 patients taking insulin glargine and 59 on IDegAsp with comparable glycemic control.

Novo Nordisk is exploring the clinical profile of insulin degludec and IDegAsp in one of the largest ever phase 3a clinical trial programs in the field of insulin therapy, BEGIN™ and BOOST™, with more than 10,000 patients.

Adverse events

The most common adverse events were headache, diarrhea and nasopharyngitis; and most were mild to moderate in severity.

About the mode of action

Insulin degludec is an investigational insulin molecule that has a distinct mode of action that provides a smooth and stable profile. The ultra-long clinical profile is derived from the soluble multi-hexamer formation and the continuous slow and stable release of insulin degludec monomers.(1)

Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk-us.com.

References

  1. Jonassen, I et al. Insulin Degludec is a new generation ultra-long-acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation. Oral Presentation no. 39-OR, presented at the American Diabetes Association (ADA) Scientific Sessions 2010, Orlando, Florida. June 2010.
  2. Zinman, B et al. Insulin degludec, a new generation ultra-long acting insulin used once-daily or three times weekly in people with type 2 diabetes: Comparison to insulin glargine. Oral Presentation no. 40-OR, presented at the American Diabetes Association (ADA) Scientific Sessions 2010, Orlando, Florida. June 2010.
  3. Heise, T et al. Once-daily use of a new generation, ultra-long acting basal insulin with a bolus boost in insulin naive people with type 2 diabetes: Comparison with insulin glargine. Oral Presentation no. 34-OR, presented at the American Diabetes Association (ADA) Scientific Sessions 2010, Orlando, Florida. June 2010.


'/>"/>
SOURCE Novo Nordisk
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
2. Sinapis Pharma Commences Phase I Trial
3. Zydus Novel Orally Administered GLP-1 Agonist - ZYOG1 to treat Diabetes and Obesity Enters Phase I Clinical Trial
4. InteKrin Therapeutics to Present Phase 2b Clinical Data for Edema at the 2010 American Diabetes Association Annual Meeting
5. DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)
6. Trius Therapeutics Obtains Special Protocol Assessment With FDA for Phase 3 Study of Torezolid Phosphate
7. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
8. MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial
9. Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
10. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
11. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
Breaking Medicine News(10 mins):